Puremed Biotech

Puremed Biotech is a South Korean biotechnology company specializing in the development of next-generation exosome-based therapeutics and cell therapies. Founded in 2017, the company focuses on treating refractory diseases, including atopic dermatitis and various solid tumors, through its proprietary platform technology. Their lead programs, such as PMB-101, leverage the unique signaling and delivery capabilities of exosomes to modulate immune responses and deliver therapeutic payloads. Puremed aims to address significant unmet medical needs by integrating advanced cell engineering with extracellular vesicle technology. The company is positioned as an innovator in the emerging field of bio-therapeutics, targeting both local and systemic inflammatory conditions.